Table 1 Odds ratio for malignancies among first-degree relatives of CML patients

From: No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia: a population-based study in Sweden

Outcome in relatives

CML, n=4287

Controls, n=20 930

OR

95% CI

Myeloid

 AML

3

12

1.22

0.34–4.33

 MDS

0

15

—

—

 AML/MDS

3

26

0.54

0.17–1.86

 CML

0

4

—

—

 MPN

6

19

1.54

0.62–3.87

 Any myeloid malignancy

8

46

0.85

0.40–1.80

Lymphoid

 NHL

12

64

0.92

0.49–1.70

 HL

1

12

0.41

0.05–3.13

 CLL

8

29

1.35

0.62–2.95

 WM

0

0

—

—

 MM

6

26

1.13

0.46–2.74

 ALL

0

10

—

—

 Any lymphoproliferative malignancy

32

163

0.96

0.66–1.40

 Any hematologic malignancy

42

211

0.97

0.70–1.36

Solid malignancies

 Gynecological (females only)

134

617

1.56

0.87–1.28

 Gastrointestinal

125

519

1.18

0.97–1.44

 Breast (females only)

97

398

1.19

0.95–1.49

 Breast (males only)

0

2

—

—

 Prostate (males only)

76

393

0.95

0.74–1.22

 Urinary tract

36

211

0.83

0.58–1.19

 Lung

32

175

0.89

0.61–1.30

 Endocrine

29

149

0.95

0.64–1.42

 Malignant melanoma

27

150

0.88

0.58–1.32

 CNS

26

94

1.35

0.88–2.09

 ENT

19

81

1.15

0.70–1.89

 Any solid malignancy

578

2673

1.06

0.97–1.17

 Any malignancy

611

2844

1.06

0.96–1.16

  1. Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CI, confidence interval; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; CNS, central nervous system, ENT, ear-nose-throat; HL, Hodgkin lymphoma; MDS, myelodysplastic syndrome; MM, multiple myeloma; MPN, myeloproliferative neoplasms; NHL, non-Hodgkin lymphoma; OR, odds ratio; WM, Waldenström macroglobulinemia.
Back to article page